Pharmaceuticals News and Research

RSS

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540.

5 Sep 2013

Ultragenyx, Kyowa Hakko Kirin To Develop Rare Bone Disease-Fighting Mab

...

4 Sep 2013

Endo, BDSI complete interim analyses of Phase III trials for BEMA Buprenorphine

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc., and BioDelivery Sciences International, Inc. announced today that the companies have completed interim analyses of both the opioid naive and opioid experienced Phase III trials for BEMA Buprenorphine.

4 Sep 2013

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Patients with coronary artery disease and low levels of "good cholesterol - or high-density lipoprotein - who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research.

4 Sep 2013

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Patients with clogged and hardened arteries who already have their blood pressure under control may benefit from an additional blood pressure-lowering medication, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

4 Sep 2013

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Actavis South Atlantic LLC and Actavis, Inc. (collectively, "Actavis") to resolve pending patent litigation in response to Actavis' abbreviated new drug application seeking approval to market generic versions of Avanir's NUEDEXTA (dextromethorphan hydrobromide/quinidine sulfate) capsules.

4 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Enanta Gets Additional $9.2M Toward Biodefense Antibiotic Development

...

3 Sep 2013

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

...

3 Sep 2013

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467.

3 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Acacia Pharma raises $23.5 million in Series B financing

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S.

3 Sep 2013

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

NPS MedicineWise is reiterating safety messages around the newer anticoagulants dabigatran (Pradaxa) and apixaban (Eliquis) following their PBS listing for preventing stroke on 1 September 2013 – and again for rivaxabaran (Xarelto) which was PBS listed in August for the same purpose.

2 Sep 2013

Debiopharm starts Debio 1347 phase I study in patients with advanced solid tumors

Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.

2 Sep 2013

Despite living with highest risk factors for heart disease, people in high income countries suffer less

Despite living with the highest risk factors for heart disease, people in high income countries suffer less from serious cardiovascular disease, says an international study by the global PURE (Prospective Urban Rural Epidemiology ) collaboration and led by McMaster University researchers.

2 Sep 2013

SPCB launches feasibility study for Certified Specialty Pharmacy Technician designation

The Specialty Pharmacy Certification Board (SPCB) announced plans to launch a feasibility study for a Certified Specialty Pharmacy Technician™ (CSPT™) designation.

31 Aug 2013

Meda signs agreement to acquire Acton Pharmaceuticals, Inc

Meda has signed an agreement to acquire the US development company Acton Pharmaceuticals, Inc. ("Acton") including the proprietary product Aerospan. Aerospan is an inhaler for the treatment of asthma that contains the active substance Flunisolide.

31 Aug 2013

BUSM professors suggest importance of eliminating healthy obese persons from unnecessary treatments

With soaring obesity rates in the U.S., the American Medical Association has classified obesity as a disease. This major shift in healthcare policy brings much needed medical attention to obese patients.

31 Aug 2013

Small chemical changes to dietary flavonoids cause large effects on human immune system

Scientists at the University of York have discovered that very small chemical changes to dietary flavonoids cause very large effects when the plant natural products are tested for their impact on the human immune system.

31 Aug 2013

Researchers develop model that completes bridge between cellular and human studies of schizophrenia

Schizophrenia is one of the most devastating neurological conditions, with only 30 percent of sufferers ever experiencing full recovery. While current medications can control most psychotic symptoms, their side effects can leave individuals so severely impaired that the disease ranks among the top ten causes of disability in developed countries.

31 Aug 2013

Pharmaceuticals News and Research

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Ultragenyx, Kyowa Hakko Kirin To Develop Rare Bone Disease-Fighting Mab

Endo, BDSI complete interim analyses of Phase III trials for BEMA Buprenorphine

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Enanta Gets Additional $9.2M Toward Biodefense Antibiotic Development

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Acacia Pharma raises $23.5 million in Series B financing

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

Debiopharm starts Debio 1347 phase I study in patients with advanced solid tumors

Despite living with highest risk factors for heart disease, people in high income countries suffer less

SPCB launches feasibility study for Certified Specialty Pharmacy Technician designation

Meda signs agreement to acquire Acton Pharmaceuticals, Inc

BUSM professors suggest importance of eliminating healthy obese persons from unnecessary treatments

Small chemical changes to dietary flavonoids cause large effects on human immune system

Researchers develop model that completes bridge between cellular and human studies of schizophrenia

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence